Empagliflozin in combination with trandolapril but not with triple therapy improves glucose and lipid metabolism in non-diabetic hypertensive model
Abstract
Our previous study demonstrated antihypertensive, anti-inflammatory and metabolic effects of SGLT-2 inhibition in non-diabetic, Ren-2 transgenic hypertensive rats (TGR). The current study aimed to compare the combination of empagliflozin with angiotensin converting enzyme inhibition (trandolapril) versus triple therapy (hydralazine, hydrochlorothiazide, reserpine). Adult male hypertensive Ren-2 transgenic rats were pretreated with these drugs for four weeks. For the following two months, the rats were concomitantly given empagliflozin. Renal function and echocardiography were analyzed throughout the study. Oral glucose tolerance test, metabolic parameters, blood pressure and heart rate were evaluated at the end of the experiment. Additionally, blood pressure and heart rate were monitored by telemetry in trandolapril-treated TGRs. Empagliflozin reduced body weight gain more in trandolapril-treated animals than in rats on triple therapy, despite the latter having higher food consumption. Beneficial effects of empagliflozin in trandolapril-treated group included decreased epididymal fat mass, improved plasma glucose and insulin sensitivity and several metabolic parameters, such as non-fasting glucose, plasma insulin, plasma NEFA, and hepatic cholesterol. There was also reduced ectopic lipid accumulation in liver, kidneys, heart and skeletal muscles, and attenuated inflammation (leptin, MCP-1, TNFα) and steatotic gene markers. BP decreased slightly in trandolapril-treated group,…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.